Ann Marie Mauer to Transforming Growth Factor alpha
This is a "connection" page, showing publications Ann Marie Mauer has written about Transforming Growth Factor alpha.
Connection Strength
0.016
-
Phase II trial of gefitinib 250 mg daily in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. Clin Cancer Res. 2005 Dec 01; 11(23):8418-24.
Score: 0.016
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.